Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...
Forty Seven is a clinical-stage immuno-oncology...
Premier operates one of the nationâs largest performance improvement alliances o...
Premier operates one of the nationâs largest ...
For 40 years, weâve worked at the intersection of health care and information te...
For 40 years, weâve worked at the intersectio...
Chiasma is focused on improving the lives of patients who face challenges associat...
Chiasma is focused on improving the lives of pa...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.